$STIM News
Last published 1d ago
- 1d agoSTIMNeuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common StockGlobeNewswire
- 1d agoSTIMNeuronetics Announces Proposed Public Offering of Common StockGlobeNewswire
- 1w agoSTIMNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook
- 1w agoSTIMNeuronetics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 1w agoSTIMNeuronetics Reports Third Quarter 2026 Financial and Operating ResultsGlobeNewswireMALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics"), a leader in interventional mental health and provider of NeuroStar® TMS technology and
- 3w agoSTIMNeuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference CallGlobeNewswireMALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook
- 2mo agoSTIMNeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR SystemGlobeNewswireMALVERN, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook
- 3mo agoSTIMNeuronetics Reports Second Quarter 2026 Financial and Operating ResultsGlobeNewswireMALVERN, Pa., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics"), a leader in interventional mental health that combines its NeuroStar® TMS technology
- 3mo agoSTIMNeuronetics and Jorey Chernett Announce Shared VisionGlobeNewswireChernett Affirms Comfort with the Company’s Capital Position and Confidence in Management’s ExecutionEstablishes Path Towards Neuronetics Board Representation MALVERN, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) --
- 3mo agoSTIMNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook
- 3mo agoSTIMGreenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, MarylandGlobeNewswireMALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook
- 3mo agoSTIMNeuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference CallGlobeNewswireMALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook
- 3mo agoSTIMAXGNNeuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management ChangesGlobeNewswireNir Naor appointed Chief Financial Officer effective July 23, 2026, bringing more than 20 years of finance and life sciences experienceCory Anderson promoted to Executive Vice President and General Manager, Greenbrook
- 4mo agoSTIMNeuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026GlobeNewswireMALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook
- 5mo agoSTIMNeuronetics Appoints Robert Greene as Senior Vice President SalesGlobeNewswireMALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
- 5mo agoSTIMNeuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026GlobeNewswireMALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
- 6mo agoSTIMNeuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS TreatmentGlobeNewswireMALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
- 6mo agoSTIMNeuronetics Reports First Quarter 2026 Financial and Operating ResultsGlobeNewswireMALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics"), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic
- 6mo agoSTIMNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life
- 6mo agoSTIMNeuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference CallGlobeNewswireMALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
- 7mo agoSTIMOptum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse PractitionersGlobeNewswireMALVERN, Pa., April 13, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
- 7mo agoSTIMNeuronetics Comments on Letter from Pointillist Family OfficeGlobeNewswireMALVERN, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
- 7mo agoSTIMNeuronetics Announces Chief Financial Officer TransitionGlobeNewswireMALVERN, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
- 7mo agoSTIMLargest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS BusinessPR NewswireJorey Chernett, the largest independent shareholder of Neuronetics, Inc. (NASDAQ: STIM) (the "Company" or "Neuronetics") owning approximately 14.12%...
- 8mo agoSTIMNeuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference CallGlobeNewswireMALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics"), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic
- 8mo agoMYGNSTIMTFXZOMDiality Appoints Peter Donato as Chief Financial OfficerBusiness WireLife sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today
- 9mo agoSTIMNeuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireAll values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro
- 11mo agoSTIMNeuronetics to Participate at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireMALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic
- 12mo agoSTIMTRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with DepressionGlobeNewswireMALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
- 1y agoSTIMNeuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition PlanGlobeNewswireDelivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% on an adjusted
- 1y agoSTIMNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life
- 1y agoSTIMNeuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational ExcellenceGlobeNewswireMALVERN, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
- 1y agoSTIMNeuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference CallGlobeNewswireMALVERN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
- 1y agoSTIMNew York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)GlobeNewswireMALVERN, Pa., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
- 1y agoSTIMNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life
- 1y agoSTIMNeuronetics, Inc. (STIM) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoSTIMNeuronetics Reports Second Quarter 2025 Financial and Operating ResultsGlobeNewswireDelivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth Generated record Greenbrook clinic revenue of $23.0 million in the quarter Reduced cash used in operations to
- 1y agoSTIMNeuronetics to Present at the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewswireMALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of
- 1y agoSTIMNeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed AdolescentsGlobeNewswireMALVERN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
- 1y agoSTIMNeuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference CallGlobeNewswireMALVERN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
- 1y agoSTIMNeuronetics Appoints New Chief Financial OfficerGlobeNewswireSteven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process
- 1y agoSTIMNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life
- 1y agoSTIMNeuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial ProgramGlobeNewswireMALVERN. Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of
- 1y agoSTIMNeuronetics Set to Join Russell 2000® and Russell 3000® IndexesGlobeNewswireMALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives
- 1y agoSTIMNeuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness MonthGlobeNewswireNew national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sharing patient and provider stories that highlight the impact
- 1y agoSTIMNeuronetics Reports First Quarter 2025 Financial and Operating ResultsGlobeNewswireMALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic
- 1y agoSTIMNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireMALVERN, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life
- 1y agoSTIMNeuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference CallGlobeNewswireMALVERN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who
- 1y agoSTIMEvernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with DepressionGlobeNewswireMALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives
- 1y agoSTIMNeuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating ResultsGlobeNewswireMALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") is issuing this press release to update the reporting of its financial results for the fourth quarter